GlassScriptPhysician profile
Kimberly Ho
NPI 1326441031
$2,787.10
in general payments reported to CMS, 2019-2025
17 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $18.65 · 2021: $178 · 2022: $721 · 2023: $842 · 2024: $510 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.31 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $692.08 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $610.07 | 2019-2025 | Total30, Dailies Total1, Eysuvis |
| Glaukos Corporation | $271.74 | 2023 | |
| Abbvie INC. | $216.18 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $194.15 | 2021-2025 | Cequa |
| Coopervision INC. | $178.44 | 2020-2025 | Misight Contact Lens |
| Bausch & Lomb Americas INC. | $114.05 | 2024-2025 | Xiidra, Alden Scleral Zenlens, Miebo |
| Allergan, INC. | $107.93 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $100.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $69.39 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $53.65 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $40.25 | 2021-2022 | |
| Harrow Eye, LLC | $37.82 | 2025 | Vevye |
| Dompe US, INC. | $34.39 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $23.96 | 2024 | Ryzumvi, Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $22.00 | 2025 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.